Martina Böhm-Weigert: Supporting Precision Dosing in Hemophilia with Fitusiran
Martina Böhm-Weigert, Scientific Support at Siemens Healthineers, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in RPTH, adding:
“QFITLIA (fitusiran) helps restore hemostasis by lowering antithrombin in individuals with hemophilia A or B, with or without inhibitors.
Maintaining the right therapeutic window is critical.
A recent study published in rpth shows that the INNOVANCE Antithrombin assay can accurately quantify antithrombin activity within the 15 to 35% range required for fitusiran dosing.
With strong precision and no interference from common hemophilia therapies, these data support confident clinical decision making in hemophilia A and B management.”
Title: Analytical validity of the INNOVANCE Antithrombin assay for the measurement of antithrombin activity at fitusiran clinical decision points
Authors: Christoph Freidel, Martina Boehm-Weigert, Christine Dahler, Marek Demissie, Hong Wang, Mingjie Liu, Shariq Ali, Ekta Seth Chhabra
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 22, 2026, 08:13How Long Does It Really Take to Recover from a Joint Bleed – EAHAD
-
Jul 22, 2026, 05:26Richard Dalyai: Can AI Safely Refill Medications?
-
Jul 22, 2026, 05:15Annie Bauzon: What Is Anemia? – Microcytic, Normocytic and Macrocytic Types Explained
-
Jul 22, 2026, 05:05Rob Maloney: What If Hemophilia No Longer Needed Lifelong Treatment?
-
Jul 22, 2026, 05:01Melina Rodriguez: First FDA-Approved VWD Prophylaxis for All Ages
-
Jul 22, 2026, 04:59Martina Wolff: Advancing Knowledge Through Global Collaboration at ISTH 2026
-
Jul 22, 2026, 04:52G. Shellye Horowitz: Hemophilia A Genetics – Hemophilia A and Pregnancy
-
Jul 21, 2026, 23:43Shadi Tabibian: The Clinical Power of Patient Stories in Rare Bleeding Disorders
-
Jul 21, 2026, 23:35Pete Stibbs: Impressed with PE Compass and Clinical Compass from Mona Ranade and Team